The Q1 results and new HIV test orders indicate the transformation plan is gaining traction. Monitor Q2 and Q3 2026 for continued revenue growth, margin expansion, and progress toward positive EBITDA. The stock's micro-cap status and historical volatility warrant caution, but the improving fundamentals support a positive bias.
Price Chart
Executive Summary
Trinity Biotech reported Q1 2026 revenue of $10.8M, up 43% YoY from $7.6M, with gross margin improving to 35.4% from 25.2% and net loss narrowing to $4.4M from $8.8M. The company also announced additional purchase orders for over 2 million units of its TrinScreen HIV test for Q3 2026 fulfillment, supporting its 2026 revenue and profitability targets. The improving financials and order momentum signal execution on the Comprehensive Transformation Plan, though the company remains unprofitable.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $10.8M, up 43% YoY from $7.6M
- Gross margin expanded to 35.4% from 25.2%
- Net loss improved to -$4.4M from -$8.8M
- Adjusted EBITDA improved to -$1.1M from -$4.0M
- Additional purchase orders for over 2 million TrinScreen HIV units for Q3 2026 fulfillment
- Rapid HIV sales of $3.7M in Q1 2026, including $2.3M from TrinScreen HIV (vs $0.4M in Q1 2025)
Financial Impact
Revenue up 43% YoY, gross margin up 10.2pp, net loss reduced by $4.4M
Risk Factors
- Company still loss-making with negative adjusted EBITDA
- Dependence on HIV test orders and global health funding
- Small market cap ($14M) with low liquidity and high volatility
- Execution risk on outsourced manufacturing scale-up
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.11 (+23.22%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.11 (−11.12%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.11 (−25.94%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.11 (+27.96%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.11 (−32.92%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.11 (−36.35%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.11 (−39.07%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.11 (+1788.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers